7 results about "Antibody therapy" patented technology

This invention discloses a bispecific nanobody targeting CXCL1 and PD-L1 and its applications, belonging to the fields of antibody engineering and bioengineering technology. The bispecific nanobody targeting CXCL1 and PD-L1 comprises at least one nanobody recognizing CXCL1 and one nanobody recognizing PD-L1, with the nanobody monomers linked by a linker. The bispecific nanobody targeting PD-L1 / CXCL1 provided by this invention has a unique structure, enabling it to specifically recognize and bind to both CXCL1 and PD-L1. It achieves an affinity of 1.08 nM for CXCL1 and 1.09 nM for PD-L1, effectively preventing immune escape-induced resistance to antibody therapy, making it suitable for a wider range of patients, and providing a new approach for CRC treatment.

Targeting immunosuppressive B cell populations using bispecific or multivalent targeting molecules presents a potential pathway for therapeutic interventions that effectively modulate antitumor immune responses and improve therapeutic outcomes. Therefore, we provide engineered antibody-based therapeutics that can effectively and selectively target immunosuppressive B cell populations for the treatment of cancer. [Solution] A multispecific antibody is provided comprising a CD19 antigen-binding component configured to bind to CD19 and a CD38 antigen-binding component configured to bind to CD38, wherein the CD19 antigen-binding component comprises an antibody or an antigen-binding fragment thereof, and the CD38 antigen-binding component comprises an antibody or an antigen-binding fragment thereof.

The present invention relates to a composition and method capable of effectively predicting the therapeutic responsiveness of a subject to an antibody therapeutic agent for asthma, using blood EDN levels or urine EDN levels. In particular, the present invention can significantly increase the efficiency of predicting therapeutic responsiveness by configuring, as appropriate parameters, blood and urine EDN levels together with the number of blood eosinophils that were conventionally used to predict therapeutic responsiveness to antibody therapeutic agents for asthma. Therefore, the present invention can be usefully utilized for predicting the therapeutic responsiveness of a subject to various antibody therapeutic agents for asthma, such as mepolyizumab, resluzumab, and dupilumab.

Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies.

The present application provides a compound useful as an effective ingredient of a therapeutic drug composition for a cancer associated with immune cell activation or a cancer resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy. The present inventors have researched a compound useful as an effective ingredient of a therapeutic drug composition for a cancer associated with immune cell activation or a cancer resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy, and have confirmed that a heteroaryl formamide compound has DGKζ (DGKzeta) inhibitory action, thereby completing the present application. The heteroaryl formamide compound of the present application has DGKζ inhibitory action, and can be used as a therapeutic agent for a cancer associated with immune cell activation or a cancer resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy.

A compound useful as an active ingredient of a pharmaceutical composition for treatment of colorectal cancer (except for mismatch repair-deficient bowel cancer) is provided. In an embodiment, a compound useful as an active ingredient of a pharmaceutical composition for treatment of colorectal cancer (except for mismatch repair-deficient bowel cancer) related to activation of immune cells or colorectal cancer (except for mismatch repair-deficient bowel cancer) having resistance to anti-PD-1 antibody / anti-PD- LI antibody therapy is provided. In addition, a pharmaceutical composition, comprising administering an effective amount of a compound, for example, a DGK ξ inhibitor, to the subject in combination with a combination therapy for treatment of colorectal cancer (except for mismatch repair-deficient bowel cancer) and / or non-small cell lung cancer is provide. The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of colorectal cancer (except for mismatch repair-deficient bowel cancer), in an embodiment, for treatment of colorectal cancer (except for mismatch repair- deficient bowel cancer) related to activation of immune cells or colorectal cancer (except for mismatch repair-deficient bowel cancer) having resistance to anti-PD-1 antibody / anti-PD- LI antibody therapy, and found that a pyridazinyl-thiazolecarboxamide compound has DGK ξ (DGKzeta) inhibitory effect, leading to completion of the present invention. The pyridazinyl-thiazolecarboxamide compound of the present invention has DGK ξ inhibitory effect, and can be used as a therapeutic agent for treatment of colorectal cancer (except for mismatch repair-deficient bowel cancer), in an embodiment, for treatment of colorectal cancer (except for mismatch repair-deficient bowel cancer) related to activation of immune cells or colorectal cancer (except for mismatch repair-deficient bowel cancer) having resistance to anti-PD-1 antibody / anti-PD-Ll antibody therapy. In addition, the pharmaceutical composition, comprising administering an effective amount of the pyridazinyl-thiazolecarboxamide compound of the present invention or a salt thereof to the subject in combination with a combination therapy can be used as a therapeutic agent for treatment of colorectal cancer (except for mismatch repair-deficient bowel cancer) and / or non-small cell lung cancer.

Provided is a compound that is useful as an active ingredient of a medicinal composition for treating cancer related to immunocyte activation or cancer resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy. The present inventors studied compounds being useful as an active ingredient of a medicinal composition for treating cancer related to immunocyte activation or cancer resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy and confirmed that a pyridazinyl thiazolecarboxamide compound has an effect of inhibiting DGKξ (DGKzeta) to thereby complete the present invention. The pyridazinyl thiazolecarboxamide compound of the present invention has an effect of inhibiting DGKξ and is usable as a therapeutic agent for cancer related to immunocyte activation or cancer resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy.